A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Trial Profile

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 17 Jun 2018 Results of subgroup ad-hoc analysis of ASPIRE and ENDEAVOR, evaluating OS based on prior autologous stem cell transplant (ASCT) status presented at the 23rd Congress of the European Haematology Association
    • 11 Jun 2018 According to an Amgen media release, the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from this trial to the U.S. Prescribing Information for KYPROLIS (carfilzomib).
    • 01 Apr 2018 Results of subgroup analysis of ASPIRE and ENDEAVOR trials assessing efficacy published in the Hematological Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top